FASLG and neoplasm: Next to test human FasL cleavage in the tumor-immune context, we intraperitoneally injected ID8OVA tumor harboring C57BL/6 animals either with 50 μg avelumab alone or 50 μg avelumab + 25 μg huIgG1-FasL.